奧泰生物(688606.SH):全資孫公司取得土地使用權
格隆匯6月16日丨奧泰生物(688606.SH)公佈,2025年3月20日召開第三屆董事會第十一次會議,審議通過了《關於<公司全資子公司向全資孫公司增資以實施對外投資>的議案》,同意公司下屬全資孫公司凡凌生物科技(杭州)有限責任公司(簡稱“凡凌生物”)與杭州臨平經濟技術開發區管理委員會擬簽訂招商協議書,並通過凡凌生物負責土地招拍掛及廠房建設,用於年產2億人份診斷試劑及電子儀器項目,本項目總投資不低於3億元人民幣。近日,就上述投資建設項目用地,凡凌生物以自有資金人民幣1,915萬元競拍取得了國有建設用地使用權(宗地編號:臨平政工出[2025]4號),並與杭州市規劃和自然資源局臨平分局正式簽署完成《國有建設用地使用權出讓合同公證書》。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.